Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? - Wikidata - wikimedia - TriplyDB

Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?

Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?

http://www.wikidata.org/entity/Q33988898

about

Mycolactone-Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with Fibrin Deposition in Buruli Ulcer Lesions Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease A severe case of Buruli ulcer disease with pleural effusions Experimental infection of the pig with Mycobacterium ulcerans: a novel model for studying the pathogenesis of Buruli ulcer disease.Clinical features and management of a severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co-infection.Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study Spontaneous clearance of a secondary Buruli ulcer lesion emerging ten months after completion of chemotherapy--a case report from Togo.Detection of viable Mycobacterium ulcerans in clinical samples by a novel combined 16S rRNA reverse transcriptase/IS2404 real-time qPCR assay.Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections.Establishment of quantitative PCR (qPCR) and culture laboratory facilities in a field hospital in benin: 1-year results.Immunohistochemical monitoring of wound healing in antibiotic treated Buruli ulcer patients.Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection Treatment Outcome of Patients with Buruli Ulcer Disease in Togo.Challenges Associated with Management of Buruli Ulcer/Human Immunodeficiency Virus Coinfection in a Treatment Center in Ghana: A Case Series Study.Buruli-ulcer induced disability in ghana: a study at apromase in the ashanti region.Genetic Susceptibility and Predictors of Paradoxical Reactions in Buruli Ulcer Local Cellular Immune Responses and Pathogenesis of Buruli Ulcer Lesions in the Experimental Mycobacterium Ulcerans Pig Infection Model.Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression.Local Heat Application for the Treatment of Buruli Ulcer: Results of a Phase II Open Label Single Center Non Comparative Clinical Trial.Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.Comparison of two assays for molecular determination of rifampin resistance in clinical samples from patients with Buruli ulcer disease.History, biology and chemistry of Mycobacterium ulcerans infections (Buruli ulcer disease).Pathogenesis of skin ulcers: lessons from the Mycobacterium ulcerans and Leishmania spp. pathogens.Revisiting Buruli ulcer.Infiltrating leukocytes surround early Buruli ulcer lesions, but are unable to reach the mycolactone producing mycobacteria.Mapping biopsy for Buruli ulcer self-medicated with occlusive dressing.

P2860

Q27318699-F28AD58E-507D-4EA0-8CDE-68513B5B51CB Q28552524-141BE29B-D6CE-40E5-8AF9-93F80EF779F4 Q33778730-44EB7344-F7BF-4D19-941B-E25EAA696FD9 Q33881961-4023D251-1839-4A1F-88B3-75C8B308A758 Q34006790-D1C83082-26AA-48A9-8BF2-FC3C1438E871 Q34137837-273D4A1B-1FD4-40CB-959E-FCDB49C3F37F Q34364979-84685A09-4C89-47AA-9076-2F3B332830E8 Q34406837-348D249A-F8E3-42E1-B1B7-3C0EDD6C7ACB Q34500901-620E4047-041D-4618-A277-DFD8F1CB45CA Q34702499-9346DEB9-3C1E-4F4C-BA4C-947260C04AE8 Q34978950-11C6E6EF-0B5A-41B5-9D07-C4010F1C222C Q35036322-FA984274-7D36-4631-A68F-2ECC7F7E847B Q35156761-5119C708-4781-4114-806F-24D6AB7BA9A4 Q35625819-6A54ABB8-5D00-43E3-B318-DBAA36BD10F1 Q35689285-53B76C9A-E225-4781-BB0B-5ED9F32E9917 Q35790836-03296533-CFA6-495F-9668-90E61C39D50D Q35810457-C2B6C553-58CA-4AE0-A750-EF31C6B98E6F Q35933855-C6FD328F-C757-4DAD-8D8C-B100E806D55B Q35993770-62F77FAC-8D1F-4B1F-A6FB-59EB00245AC8 Q35994923-2F2EC75E-6CBE-4BC8-8215-01A8FDA7646F Q36002996-211EB79C-8863-45EB-A69E-C64A3B78936A Q36291527-FD4EF69B-61DE-4FC9-9FD8-D8427D4E80C3 Q36446126-C9783821-E170-4693-8917-AF3980BA6867 Q37544684-BC84EAB4-199F-498D-A9FE-A58764F76397 Q37713494-CB9A17AB-FACB-42B8-8673-9F4B9B7F268A Q38157768-0BE172D5-3066-4BF2-A64A-B5503CE161DA Q38180374-A13795F7-AF3C-467D-9967-6D74778D72EF Q38579126-66C3EE38-9EED-4E1B-8AF4-3A8ADD489B43 Q39413440-DB49EEEC-6ED6-4025-933A-01F67B165ECD Q40054248-4EB1A24A-62A5-4023-AC24-3DB00E19C0F5

P2860

Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?

http://www.wikidata.org/entity/Q33988898

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Secondary Buruli ulcer skin le ...... vidence for immune protection?

@ast

Secondary Buruli ulcer skin le ...... vidence for immune protection?

@en

type

label

Secondary Buruli ulcer skin le ...... vidence for immune protection?

@ast

Secondary Buruli ulcer skin le ...... vidence for immune protection?

@en

prefLabel

Secondary Buruli ulcer skin le ...... vidence for immune protection?

@ast

Secondary Buruli ulcer skin le ...... vidence for immune protection?

@en

P1433

Q33988898-BD318BB9-4070-45E9-85C8-182F583D7CC6

P1476

Q33988898-2054F27F-773B-4D22-BFB1-1B729DBD078D

P2093

Q33988898-1DA89C32-074D-41DC-B01F-0B7E3C58E168

Q33988898-49613889-0476-49C7-A345-1691965ABAAE

Q33988898-49A7063D-844A-4C1D-A9D7-21CBD17272EC

Q33988898-73A4FDA9-C4A2-4E52-8406-4B4ECF8B28AC

Q33988898-80823D5D-39AF-48DE-8272-13FCEE9CC7EC

Q33988898-8F738635-8342-4A29-AABD-39E4140E1D35

Q33988898-95E060F1-F4FD-4808-BFD5-F9EB0928602E

P2860

Q33988898-102E834F-B083-402D-BBBC-2BE08A80ABEE

Q33988898-14895676-0F4D-4AEB-AF0A-2AA8AED70E84

Q33988898-1977B56F-B5B7-447E-91F3-572A4B9824C1

Q33988898-1F53D897-F803-4B97-B7CA-E95EE284EA08

Q33988898-211F0E15-8693-47C8-83D8-218E51BD9D6C

Q33988898-2A518202-804B-4765-8757-13A396EE1379

Q33988898-2D4B26D0-4105-4EBC-889B-44288F297FBF

Q33988898-2FC4B3CE-8844-4D01-82EA-AA4E45F658B5

Q33988898-3D085D93-AD93-4FFE-8533-2FD241663CA9

Q33988898-43043C6C-F89E-4DFA-A2B3-455E5FB90F5F

P304

Q33988898-E630D357-BB4F-4E06-9A47-E95819E9A8CC

P31

Q33988898-6EB250CE-2260-45B1-BC57-6B73D10D7F4E

P356

Q33988898-99231CAB-40A1-4CE3-A2EC-B646724D5A29

P407

Q33988898-A6231FC3-DA6E-420E-9CF0-44EFEB8E41D3

P433

Q33988898-8B5276C7-B85A-44FA-A9D5-D16945BF5AF9

P478

Q33988898-42BB535B-AE9A-469E-8C74-00EFA0142092

P577

Q33988898-8F3387BB-FCB8-49D7-B10E-5D937FF9A88F

P5875

Q33988898-8EC0118C-DBC9-4672-811C-C2E04C2A58BF

P698

Q33988898-122B03A4-F359-49AB-B056-1866E1DFFDAF

P921

Q33988898-C8D865E7-9A3D-4097-84CE-DD38A764B4A3

P932

Q33988898-BFBAA1E5-CC74-4286-8871-72D51ED15F7C

P356

JOURNAL.PNTD.0001252

P1433

PLOS Neglected Tropical Diseases

P1476

Secondary Buruli ulcer skin le ...... vidence for immune protection?

@en

P2093

Ambroise Adeye

http://www.w3.org/2001/XMLSchema#string

Annick Chauty

http://www.w3.org/2001/XMLSchema#string

Gerd Pluschke

http://www.w3.org/2001/XMLSchema#string

Hugues Koussemou

http://www.w3.org/2001/XMLSchema#string

Marie-Françoise Ardant

http://www.w3.org/2001/XMLSchema#string

Marie-Thérèse Ruf

http://www.w3.org/2001/XMLSchema#string

Roch Christian Johnson

http://www.w3.org/2001/XMLSchema#string

P2860

Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control.

Buruli ulcer in Ghana: results of a national case search

Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages

Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence

Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin

"Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure.

Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot.

Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).

Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.

Severe multifocal form of buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms.

P304

e1252

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PNTD.0001252

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51560053

http://www.w3.org/2001/XMLSchema#string

P698

21829740

http://www.w3.org/2001/XMLSchema#string

P921

P932

3149035

http://www.w3.org/2001/XMLSchema#string